← All trials
NCT04992260
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2021
- Primary completion
- Nov 25, 2021
- Completion date
- Apr 1, 2023
- First posted
- Aug 5, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 14000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sinovac Biotech Co., LtdLead sponsor
- Pontificia Universidad Catolica de ChileOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.